Glyscend, Inc. delivered an oral presentation highlighting preclinical data from a study of its oral proprietary polymer duodenal exclusion therapy during the 57th Annual Meeting of the European Association for the Study of Diabetes on September 28, 2021. Data from earlier results were presented previously this year at the American Diabetes Association 80th Scientific Sessions. Glyscend has also been selected to present at the Obesity Society Annual Meeting in November 2021, focusing on the role of polymer-based duodenal exclusion therapy as an alternative to gastric bypass surgery for the management of obesity.
End of Year Update: 2020 Life Science Venture Capital Funding Roundup in the BioHealth Capital Region
![](https://biobuzz.io/wp-content/uploads/2020/12/2020-Life-Science-Venture-Capital-Funding-Roundup-1-300x300.png)
This has certainly been a year unlike any other for BioHealth Capital Region (BHCR) life science companies of all sizes and kinds. Just a few months into 2020, the coronavirus pandemic swept the region, seriously disrupting, albeit temporarily, the best laid plans of aspiring founders, entrepreneurs, emerging startups, pre-clinical and more established, larger biohealth organizations in Virginia, Washington, D.C. and Maryland.
21 Emerging Life Science Companies Fueling Maryland’s Biohealth Ecosystem
![](https://biobuzz.io/wp-content/uploads/2020/09/21-maryland-life-science-in-MD-300x300.png)
Maryland is the epicenter of biotech and life science innovation in the BioHealth Capital Region (BHCR). The state is home to a burgeoning life science ecosystem, including a rapidly growing cell and gene therapy industry, a robust and growing advanced biomanufacturing environment, and a deep network of leading research universities and critical government life science research entities.